Bentamapimod
CAS: 848344-36-5
Ref. 3D-FB146407
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
- AS-602801
Bentamapimod is a drug candidate which has been shown to inhibit the activity of survivin, a protein that regulates cell death. It also affects signal pathways in prostate cancer cells and endometrial cancer cells. Bentamapimod has been tested in transfection experiments on human prostate cancer cells and mouse tumor cells. This drug candidate inhibits the activity of survivin by covalently binding to it, leading to increased apoptosis and decreased growth of these cancers. Bentamapimod has also been shown to inhibit the growth of bacteria by disrupting their cell membranes and inhibiting their ability to synthesize proteins.
Bentamapimod may have therapeutic effects for a number of metabolic disorders including type 2 diabetes, obesity, insulin resistance, hyperlipidemia, fatty liver disease, and cardiovascular diseases due to its ability to affect signal pathways involved in metabolism.
